TherapeuticsMD (TXMD) Depreciation & Amortization (CF) (2010 - 2026)

TherapeuticsMD has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $94000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 1.05% year-over-year to $94000.0; the trailing twelve-month figure through Mar 2026 stood at $383000.0 (down 18.68% YoY), and the FY2025 full-year result was $384000.0, down 24.56% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $94000.0, down from $97000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $637000.0 in Q4 2023, with the low at $27000.0 in Q1 2023.
• Historically, Depreciation & Amortization (CF) has averaged $182529.4 across 5 years, with a median of $129000.0 in 2023.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) sank 91.79% — and 2024, when it surged 392.59%.
• TherapeuticsMD's Depreciation & Amortization (CF) stood at $309000.0 in 2022, then soared by 106.15% to $637000.0 in 2023, then sank by 84.3% to $100000.0 in 2024, then slipped by 3.0% to $97000.0 in 2025, then retreated by 3.09% to $94000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $94000.0 (Q1 2026), $97000.0 (Q4 2025), and $96000.0 (Q3 2025), per Business Quant data.